Literature DB >> 23423744

Off-label use of cancer drugs: a benchmark is established.

Monika K Krzyzanowska.   

Abstract

Mesh：

Year:  2013        PMID： 23423744     DOI： 10.1200/JCO.2012.46.9460

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Next-generation sequencing in the clinic.

Authors:  Jason Y Park; Larry J Kricka; Paolo Fortina
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

2.  Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer.

Authors:  Ya Zhang; Xuefeng Wu; Yan Kai; Chia-Han Lee; Fengdong Cheng; Yixuan Li; Yongbao Zhuang; Javid Ghaemmaghami; Kun-Han Chuang; Zhuo Liu; Yunxiao Meng; Meghana Keswani; Nancy R Gough; Xiaojun Wu; Wenge Zhu; Alexandros Tzatsos; Weiqun Peng; Edward Seto; Eduardo M Sotomayor; Xiaoyan Zheng
Journal:  JCI Insight       Date:  2019-12-19

3.  Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Authors:  Paul R Massey; Ruibin Wang; Vinay Prasad; Susan E Bates; Tito Fojo
Journal:  Oncologist       Date:  2016-02-17

Review 4.  Tissue-specific tumorigenesis: context matters.

Authors:  Günter Schneider; Marc Schmidt-Supprian; Roland Rad; Dieter Saur
Journal:  Nat Rev Cancer       Date:  2017-03-03       Impact factor: 60.716

Review 5.  Personalized cancer therapy-leveraging a knowledge base for clinical decision-making.

Authors:  Ecaterina Ileana Dumbrava; Funda Meric-Bernstam
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

Review 6.  A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants.

Authors:  Xuanyi Li; Jeremy L Warner
Journal:  Front Cell Dev Biol       Date:  2020-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.